Navigation Links
Delcath to Present at the JMP Securities Research Conference
Date:5/5/2011

NEW YORK, May 5, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at The Tenth Annual JMP Securities

Research Conference on Wednesday, May 11, 2011 at 10:00 AM PT in San Francisco. Mr. David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only. Delcath will offer a live audio webcast of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentation will be available for 90 days, also at www.delcath.com.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company received CE Mark approval for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales for the Hepatic CHEMOSAT delivery system in the EEA, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, if any, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are madeContact Information:Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-896-6818/646-445-4801

646-688-0425
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
2. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
3. Delcath to Update Investors on FDA Meeting
4. Delcath Expands Board of Directors With Appointment of Gabriel Leung
5. Delcath to Present at Upcoming Investor Conferences
6. Delcath Systems Receives Refusal to File Letter From FDA
7. Delcath Achieves ISO 13485 Certification
8. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
9. Delcath Systems Announces Third Quarter Progress Report Conference Call
10. Delcath Strengthens Research and Development Team with Key Appointments
11. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 Diplomat Pharmacy, Inc. ... Michigan residents. Naloxone ... Flint retail pharmacy, G-3320 Beecher Road. ... the Food and Drug Administration, is intended to block ... slowed breathing, and loss of consciousness. The medication is ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... --   Second-quarter 2017 revenues ... per share from continuing operations ... percent to $110 million ... $161 million Second-quarter 2017 ... increased 8 percent to $0.93 ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... ... Elemental LED, a leading U.S. based engineering and technology company that ... honored with Architectural SSL Product Innovation Awards (PIA) for the most innovative ... LED, provides a wide variety of superior quality linear, task, and accent LED lighting ...
(Date:8/17/2017)... ... August 17, 2017 , ... In its just released 2018 ... and Harry Nelson. This is the third consecutive year that Hardiman and Mills have ... were both recognized for expertise in Health Care Law while Mills was recognized in ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, ... number of changes to the smartwatch market. As of June 2017, nearly nine percent ... the six months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast ...
(Date:8/17/2017)... ... 17, 2017 , ... Momkus McCluskey Roberts LLC recently announced it ... member of the firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined ... in matters of employment litigation, commercial litigation and business disputes. Her experience includes all ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... Business Development Group, a Florida-based oncology business advisor to oncology practices, announced today ... the dollar amount of attributable savings from resolving critical clinical issues that would ...
Breaking Medicine News(10 mins):